Loading...
In patients with chronic limb-threatening ischemia (CLTI), endovascular lower-extremity revascularization for infrapopliteal peripheral artery disease (PAD) has been associated with high rates of technical failure and need for repeat revascularization. In the industry-funded, randomized LIFE-BTK trial, involving 261 patients with CLTI and below-knee artery disease, an everolimus-eluting resorbable vascular scaffold device outperformed balloon angioplasty alone on the primary efficacy end point — freedom from above-ankle amputation of the target limb, target-vessel occlusion, clinically driven repeat revascularization of the target lesion, and target-lesion restenosis — at both 1 year and 2 years. We now have 3-year data.
Th…